Pharsight

Skelaxin generic

Skelaxin is a musculoskeletal conditions treatment owned by King Pharmaceuticals. The drug contains the active ingredient metaxalone and was first authorized for market use on August 30, 2002. An oral tablet, Skelaxin has 1 patent, none of which have expired.

When will Skelaxin generic be available?

The generic version of Skelaxin has the potential to be released after February 6, 2026. This date marks the expiration of its last patent, US7122566 titled 'Metaxalone products, method of manufacture, and method of use'.

Skelaxin uses

With the active ingredient metaxalone, Skelaxin is used in the treatment of musculoskeletal conditions. The properties of metaxalone contribute significantly to the effectiveness of the drug.

Skelaxin patent expiration

Skelaxin holds a single patent named 'Metaxalone products, method of manufacture, and method of use' (US7122566), which expires on February 6, 2026. This patent expiry will likely cue the release of Skelaxin generic. Below are the details of the patent:

Skelaxin dosage

Want to ask something?